Sutton Wealth Advisors Inc. - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 231 filers reported holding NEKTAR THERAPEUTICS in Q2 2022. The put-call ratio across all filers is 0.20 and the average weighting 0.0%.

Quarter-by-quarter ownership
Sutton Wealth Advisors Inc. ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q3 2022$602
-96.5%
188
-94.0%
0.00%
-100.0%
Q1 2022$16,995
+107.2%
3,153
+419.4%
0.01%
+100.0%
Q4 2021$8,201
-18.6%
607
+8.2%
0.00%
-25.0%
Q3 2021$10,076
+4.7%
5610.0%0.00%0.0%
Q2 2021$9,627
-14.2%
5610.0%0.00%0.0%
Q1 2021$11,220
+17.6%
5610.0%0.00%0.0%
Q4 2020$9,537
+2.5%
5610.0%0.00%
-20.0%
Q3 2020$9,307
-28.4%
5610.0%0.01%
-28.6%
Q2 2020$12,993
+29.7%
5610.0%0.01%
+16.7%
Q1 2020$10,0145610.01%
Q3 2019$0
-100.0%
0
-100.0%
0.00%
Q2 2019$427
-57.6%
12
-60.0%
0.00%
-100.0%
Q1 2019$1,008
+2.2%
300.0%0.00%0.0%
Q4 2018$986
-88.8%
30
-79.2%
0.00%
-83.3%
Q3 2018$8,778
-56.5%
144
-65.1%
0.01%
-57.1%
Q2 2018$20,167
-21.3%
413
+71.4%
0.01%
-22.2%
Q1 2018$25,609
-81.5%
241
-89.6%
0.02%
-82.2%
Q4 2017$138,312
+204.4%
2,316
+22.3%
0.10%
+188.6%
Q3 2017$45,432
+10.6%
1,893
-9.9%
0.04%
+6.1%
Q2 2017$41,094
-15.3%
2,102
+1.6%
0.03%
-19.5%
Q1 2017$48,536
+153.7%
2,068
+32.6%
0.04%
+141.2%
Q4 2016$19,129
-28.6%
1,5590.0%0.02%
-29.2%
Q3 2016$26,784
+20.7%
1,5590.0%0.02%
+14.3%
Q2 2016$22,185
+3.5%
1,5590.0%0.02%
+5.0%
Q1 2016$21,4361,5590.02%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q2 2022
NameSharesValueWeighting ↓
Rhenman & Partners Asset Management AB 1,350,000$22,950,0001.87%
MAVERICK CAPITAL LTD 6,655,625$113,146,0001.81%
Camber Capital Management LP 2,500,000$42,500,0001.49%
Bellevue Group AG 3,866,258$65,726,0000.75%
Adero Partners, LLC 51,500$876,0000.75%
Goodman Financial Corp 108,342$1,842,0000.64%
CM Management, LLC 35,000$595,0000.55%
OSTERWEIS CAPITAL MANAGEMENT INC 424,504$7,217,0000.43%
RICE HALL JAMES & ASSOCIATES, LLC 568,379$9,662,0000.34%
Burleson & Company, LLC 107,736$1,832,0000.32%
View complete list of NEKTAR THERAPEUTICS shareholders